In addition to fasting dyslipidemia, postprandial hyperlipidemia with increases in triglyceride-rich lipoproteins is also associated with ASCVD [109]. Similar to fasting dyslipidemia, accumulation of postprandial triglyceride-rich lipoproteins is driven by overproduction and/or decreased catabolism of these par...
Familial Combined Hyperlipidemia (FCHL):FCHL is the most common genetic dyslipidemia with a prevalence of 1:100. It is present in 40% of myocardial infarction survivors. It is an autosomal dominant condition with variable penetrance. FCHL presents with elevated TG, LDL-C, and apo-B levels an...
Controls were selected from primary care clinics at Rhode Island Hospital and South Shore Medical Center and were confirmed to not have a history of GA and skin diseases associated with hyperlipidemia, such as necrobiosis lipoidica. The records of patients serving as controls were matched to cases...
autosomal recessive, or X-linked. Some examples of primary dyslipidemia are familial hypercholesterolemia, familial hypertriglyceridemia, familial combined hyperlipidemia, and familial dysbetalipoproteinemia. The estimated prevalence of familial
Dimitri P Mikhailidis has given talks and attended conferences sponsored by MSD, AstraZeneca and Libytec. Christos S Mantzoros has no conflicts related to NAFLD/NASH or hyperlipidemia.References (301) A. Mishra et al. Epidemiology and natural history of non-alcoholic fatty liver disease J Clin...
The single nucleotide polymorphism -1131T4C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia. J Mol Med 2003; 81: 645–654. 42 Smith CE, Tucker KL, Lai CQ, Parnell LD, Lee YC, Ordovas JM. Apolipoprotein A5 and lipoprotein lipase...
1 Mortality from CHD has been declining for more than 4 decades, in part because of reduced smoking, control of hyperlipidemia and hypertension, and improved treatment of acute CHD events.2 Unfortunately, improvements have been less marked for individuals with low socioeconomic status (SES), who ...
6. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92:3172–3177. 7. Hossain P, Kawar B, El NM. Obesity and diabetes in the ...
Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial Clin Ther, 35 (2013), pp. 1350-1360 e1 View in ScopusGoogle Scholar 16 K. Bush, D.R. Kivlahan, M.B. McDonel...
Unfortunately to date, no data on the efficacy of evolocumab and alirocumab among HIV-infected subjects are available. However, a forthcoming randomized trial (NCT02833844) will evaluate safety, tolerability, and efficacy on LDL-C of evolocumab in 450 subjects with HIV and with hyperlipidemia and/...